|
| |
- Determining a treatment plan for patients
undergoing thrombotic event by monitoring P-selectin (USN 6,230,713;
issued May 15, 2001). Ownership: BTG International, Dalesandro/Gurbel/Serebruany
- Methods for inhibiting platelet activation
with selective serotonin reuptake inhibitors (USN 6,245,782;
issued June 12, 2001). Ownership: HeartDrug
- Methods of treatment of thrombotic events
(USN 10/106,958, filed March 25, 2002.
Ownership: HeartDrug/BTG International
- Methods for inhibiting platelet activity with
valsartan, and valeryl 4-hydroxy-valsartan (USN 60/395,014 filed
August 1, 2002). Ownership: Novartis/HeartDrug
- Methods for inhibiting platelet activation
with selective serotonin reuptake inhibitors (USN 6,552,014;
issued April 22, 2003). Ownership: HeartDrug
- Use of dypiridamole and mopidamole for treatment
and prevention of thromboembolic disease and disorders caused
by excessive formation of thrombin and/or by elevated expression
of thrombin receptors (USN60/465,168, filed April 24, 2003).
Ownership –Boehringer Ingelheim/ HeartDrug
- Method for inhibiting platelet activation
and thrombin generation with statins (HeartDrug/Pfizer 10 /
811, 563)
|
 ..
HOME
|
|
